QURE: Pivotal Three-Year Huntington’s Data Will Drive Approval and Market Uptake

Analysts have adjusted the uniQure fair value estimate from $64.47 to $69.38, reflecting updated assumptions around AMT-130 approval odds, revenue potential, and valuation multiples following several recent price target changes and upgrades across the Street.

Analyst Commentary

Recent Street research around uniQure centers on the shifting regulatory outlook for AMT-130 in Huntington's disease and what that might mean for valuation, execution risk, and longer term growth potential.

Bullish Takeaways

• Bullish analysts view the FDA feedback on the Type B meetings as a key de risking event for AMT-130, since the agency indicated that three year Phase 1/2 data could form the primary basis of a biologics license application for accelerated approval. This is seen as removing a major regulatory overhang on uniQure.
• Several bullish analysts reference AMT-130 as having one of the clearest near term U.S. filing paths in Huntington's disease, which they see as supportive of higher fair value ranges and increased confidence in future revenue potential tied to this program.
• Price targets have been reset materially higher by multiple firms, with figures such as US$46, US$60, US$65, US$68, US$70 and US$80 cited. Bullish analysts tie these changes to updated probability of success assumptions, larger modeled peak sales for AMT-130 and removal of what they saw as overly conservative regulatory discounts.
• Some research points to the FDA being more open to accelerated approval for Huntington's disease than previously thought, which bullish analysts interpret as constructive for uniQure execution on the planned BLA submission and for potential commercial ramp once confirmatory data mature.

Bearish Takeaways

• Even with higher price targets, some analysts retain more neutral stances and emphasize that AMT-130 still needs to clear multiple steps, including successful BLA review, confirmatory study alignment and longer term durability data. This group sees residual execution and regulatory risk that could limit upside if outcomes are less favorable than modeled.
• Bearish analysts or more cautious voices highlight that recent optimism is heavily concentrated in a single asset. They flag concentration risk if AMT-130 development timelines slip, if subsequent data do not match the initial package used for filing, or if competitive therapies progress faster.
• One large bank maintains a Neutral rating even after lifting its target to US$46. This reflects a view that the recent share price move following the accelerated approval communication already captures a meaningful portion of the upgraded scenario, which reduces the margin of safety around valuation for new capital.
• There is also awareness that supportive regulatory tone can shift, as seen in the prior back and forth around trial design and sham controlled studies. Cautious analysts remind investors that changes in FDA guidance, or a stricter stance at final review, could weigh on uniQure if expectations stay elevated while the program progresses.

What’s in the News for uniQure

• uniQure reached alignment with the FDA to submit a Biologics License Application for AMT-130 in Huntington’s disease under the accelerated approval pathway using three year Phase 1/2 data as the primary package. Source: Q2 2026 earnings call and Type B meeting update.
• The company plans a randomized confirmatory study in Huntington’s disease that uses standard of care as the control arm and total functional capacity at 36 months as the primary endpoint instead of a sham procedure. Source: Q2 2026 earnings call and FDA meeting summary.
• uniQure intends to submit Biologics License Applications for AMT-130 to the FDA and the UK MHRA in the third quarter of 2026 and expects an FDA advisory committee meeting as part of the review. Source: recent AMT-130 regulatory update.
• uniQure completed a follow on equity offering and broader capital raise of about US$259 million, extending its cash runway into 2030 to support the AMT-130 program, potential commercial launch preparations and pipeline work including AMT-260. Source: Q2 2026 earnings call and financing announcements.
• Early Phase I/IIa data for AMT-260 in refractory mesial temporal lobe epilepsy showed meaningful seizure reductions in part of the first low dose cohort and a safety profile described as mild to moderate adverse events with no related serious events reported. Source: AMT-260 clinical update.

Valuation Changes for uniQure

• Fair Value has risen modestly from $64.47 to $69.38, indicating a slightly higher central estimate for uniQure shares in the updated model.
• Discount Rate has edged higher from 7.28% to 7.49%, implying a small increase in the required return used to assess uniQure.
• Revenue Growth now reflects a higher modeled rate, moving from 175.42% to 196.52%.
• Net Profit Margin has fallen significantly from 18.92% to 5.24%, pointing to a much leaner profitability assumption relative to earlier expectations.
• Future P/E has moved sharply higher from 85.72x to 283.77x, which implies a much richer valuation multiple on projected earnings in the revised framework.